(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act. - 2Top 10 Moving Style Architects of the Year
- 3Vote In favor of Your Favored Pizza Cover
- 46 Hints to Upgrade Your Appeal, In addition to Your Outlook
- 510 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- The race is on to turn your body into a GLP-1 factory
- In blow to Lula, Brazil Congress revives controversial environmental bill
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- Kate Middleton and Prince William unveil annual family Christmas card photo with George, Charlotte and Louis
- A hospital discharged a woman in labor. This lawmaker wants change.
- Pick Your #1 Kind Of Treat
- Car Investigation: A Survey of \Past the Outside\ Car
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- The Best Competitors of the 21st Hundred years
